Biogen Critics Are Not Impressed By Aduhelm Price Cut

By Gabrielle Wanneh / December 20, 2021 at 4:57 PM
Critics of Biogen are not impressed by the company’s plan to cut the annual price of its Alzheimer’s drug Aduhelm from $56,000 to $28,000. The price cut comes after months of pushback against the drug’s price. Private insurers and Medicaid directors say there is little evidence the drug works and there is ample evidence of its serious side effects. The company announced this month that it expects to complete the post-market trial of Aduhelm in four years instead of nine...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.